Disclosed positions
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $18,816,000 | 400,000 | SH | Call |
| ABIVAX SA | ABVX | SPONSORED ADS | $16,657,500 | 125,000 | SH | Call |
| MINERVA NEUROSCIENCES INC | NERV | COM NEW | $12,075,701 | 2,175,802 | SH | None |
| PROMIS NEUROSCIENCES INC | PMN | COM SHS | $8,163,398 | 620,319 | SH | None |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS | $5,719,854 | 284,287 | SH | None |
| AXSOME THERAPEUTICS INC | AXSM | COM | $4,036,992 | 16,493 | SH | None |
| ASSEMBLY BIOSCIENCES INC | ASMB | COM NEW | $3,847,200 | 140,000 | SH | None |
| WHITEHAWK THERAPEUTICS INC | WHWK | COM | $3,746,161 | 817,939 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $3,384,479 | 83,300 | SH | None |
| CLIMB BIO INC | CLYM | COM | $3,249,203 | 249,172 | SH | None |
| KURA ONCOLOGY INC | KURA | COM | $3,181,300 | 290,000 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $2,906,250 | 775,000 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | SPONSORED ADS | $2,772,000 | 150,000 | SH | None |
| PALISADE BIO INC | PALI | COM | $2,568,610 | 1,229,000 | SH | None |
| SOLID BIOSCIENCES INC | SLDB | COM | $2,557,030 | 255,959 | SH | None |
| AN2 THERAPEUTICS INC | ANTX | COM | $2,547,365 | 526,315 | SH | None |
| UROGEN PHARMA LTD | URGN | COM | $2,545,934 | 69,183 | SH | None |
| PERSPECTIVE THERAPEUTICS INC | CATX | COM NEW | $2,536,897 | 743,958 | SH | None |
| IDEAYA BIOSCIENCES INC | IDYA | COM | $2,515,725 | 67,500 | SH | None |
| INVENTIVA SA | IVA | ADS | $2,399,544 | 634,800 | SH | None |
| ALUMIS INC | ALMS | COM | $2,151,556 | 76,459 | SH | None |
| OVID THERAPEUTICS INC | OVID | COM | $1,680,069 | 624,561 | SH | None |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | COM | $1,666,877 | 252,175 | SH | None |
| IBIO INC | IBIO | COM NEW | $682,757 | 390,147 | SH | None |
| TRAWS PHARMA INC | TRAW | COM | $663,033 | 786,236 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 2 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.